home / stock / kod / kod articles
It has been about a month since the last earnings report for Kodiak Sciences Inc. (NASDAQ: KOD). Shares have lost about 26.2% in that time frame, u...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth...
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow tra...
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. Dolby Laboratories reported quarterly ea...
StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday. StoneCo p...
Kodiak Sciences Inc (NASDAQ: KOD) said its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe t...
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholder...
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) rose 39.7% to $1.25 in pre-market trading. American Rebel announced Wednesday, that its safe ...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...